Health Canada approves IMBRUVICA(TM) by priority review
Janssen announced Health Canada has approved IMBRUVICATM (ibrutinib) for treatment of the blood cancer chronic lymphocytic leukemia. It is indicated for treatment of patients with CLL, including those with 17p deletion, who have received at least one prior therapy. November 24, 2014